Fesoterodine: A New Agent for Treating Overactive BladderByPamela Ellsworth, MD,Sandra J. Berriman, PhD,Marina Brodsky, PhDMarch 24th 2009
Pharmacotherapy Adherence and Costs Versus Nonpharmacologic Management in Overactive BladderByElise M. Pelletier, MS,Vasudha Vats, MPH,J. Quentin Clemens, MD, MSCIMarch 24th 2009
Challenges for Managing Overactive Bladder and Guidance for Patient SupportByVernon F. Schabert, PhD,Tamara Bavendam, MD,Erica L. Goldberg,Jeffrey N. Trocio, MPH,Linda Brubaker, MDMarch 24th 2009
Impact of Overactive Bladder on Work Productivity in the United States: Results From EpiLUTSByChris C. Sexton, PhD,Karin S. Coyne, PhD, MPH,Vasudha Vats, MPH,Zoe S. Kopp, PhD, MPH,Debra E. Irwin, MSPH, PhD,Todd H. Wagner, PhDMarch 24th 2009
The Total Economic Burden of Overactive Bladder in the United States: A Disease-Specific ApproachByEbere Onukwugha, PhD,Ilene H. Zuckerman, PharmD, PhD,Diane McNally, BSPharm, MS,Karin S. Coyne, PhD, MPH,Vasudha Vats, MPH,C. Daniel Mullins, PhDMarch 24th 2009
